The result showed that RIMKLB expression was lower in bladder, breast, cervical, cloln, rectum, glioblastoma, lung, pancreatic, prostate, thyroid, thymoma, stomach, uterine corpus endometrial carcinoma, and it was higher in cholangio, esophageal, head and neck, kidney, pheochromocytoma and paraganglioma, sarcomav (Figure 1A). Here, RIMKLB is linked to paraganglioma.